

Vogliviga M 0.2 Tablet

Composition (per bilayered tablet):

Metformin Hydrochloride (500mg) SR + Voglibose (0.2mg)

Description:

Vogliviga M 0.2 Tablet is a bilayered smart tablet designed for better glycemic control in type 2 diabetes mellitus. It combines Metformin, a biguanide that lowers hepatic glucose production and improves insulin sensitivity, with Voglibose, an alpha-glucosidase inhibitor that delays glucose absorption in the intestine. This dual-action formulation targets both fasting and postprandial blood glucose levels.

Indications:

- Type 2 Diabetes Mellitus (non-insulin dependent)
- Inadequate glycemic control with monotherapy
- Management of postprandial hyperglycemia

Mechanism of Action:

Metformin decreases hepatic glucose output and enhances peripheral glucose uptake and utilization, improving insulin sensitivity. Voglibose inhibits alpha-glucosidase enzymes in the intestinal brush border, delaying carbohydrate breakdown and absorption, thereby controlling post-meal blood sugar spikes.

Dosage and Administration:

One tablet once or twice daily with meals or as directed by the physician. Dosage should be individualized based on patient response and tolerability.

Contraindications:

- Renal impairment
- Diabetic ketoacidosis
- Known hypersensitivity to Metformin or Voglibose
- Severe gastrointestinal disorders

Precautions:

Use with caution in patients with liver disease, alcohol abuse, or elderly patients. Monitor renal function periodically. Risk of lactic acidosis with Metformin in certain populations.

Side Effects:

- Flatulence, bloating
- Diarrhea or abdominal discomfort
- Metallic taste (Metformin)
- Rarely, lactic acidosis (Metformin – requires emergency management)

Storage:

Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for